"Diarylquinolines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of quinoline compounds defined by the presence of two aromatic ring structures which are attached via a side chain to carbon 3 of the qunolinyl structure. The two aromatic moieties are typically NAPTHALENE and BENZENE. Several compounds in this class are used as ANTITUBERCULAR AGENTS.
Descriptor ID |
D064687
|
MeSH Number(s) |
D03.633.100.810.087
|
Concept/Terms |
Diarylquinolines- Diarylquinolines
- Diarylquinoline Derivatives
- Derivatives, Diarylquinoline
- Diaryl Quinoline Derivatives
- Derivatives, Diaryl Quinoline
- Quinoline Derivatives, Diaryl
|
Below are MeSH descriptors whose meaning is more general than "Diarylquinolines".
Below are MeSH descriptors whose meaning is more specific than "Diarylquinolines".
This graph shows the total number of publications written about "Diarylquinolines" by people in this website by year, and whether "Diarylquinolines" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2014 | 1 | 1 | 2 |
2017 | 2 | 0 | 2 |
2018 | 0 | 3 | 3 |
2019 | 1 | 0 | 1 |
2020 | 1 | 2 | 3 |
2021 | 1 | 1 | 2 |
2022 | 0 | 1 | 1 |
2023 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Diarylquinolines" by people in Profiles.
-
Emerging bedaquiline-resistant tuberculosis. Lancet Microbe. 2023 12; 4(12):e964-e965.
-
Regimens for Drug-Resistant Tuberculosis. N Engl J Med. 2023 01 12; 388(2):190.
-
Emergence of bedaquiline resistance in a high tuberculosis burden country. Eur Respir J. 2022 03; 59(3).
-
Evidence-based Definition for Extensively Drug-Resistant Tuberculosis. Am J Respir Crit Care Med. 2021 09 15; 204(6):713-722.
-
Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country. Eur Respir J. 2021 06; 57(6).
-
Bedaquiline and delamanid result in low rates of unfavourable outcomes among TB patients in Eswatini. Int J Tuberc Lung Dis. 2020 10 01; 24(10):1095-1102.
-
Bedaquiline-Resistant Tuberculosis: Dark Clouds on the Horizon. Am J Respir Crit Care Med. 2020 06 15; 201(12):1564-1568.
-
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respir Med. 2020 04; 8(4):383-394.
-
New World Health Organization Treatment Recommendations for Multidrug-Resistant Tuberculosis: Are We Well Enough Prepared? Am J Respir Crit Care Med. 2019 08 15; 200(4):514-515.
-
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018 09 08; 392(10150):821-834.